CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 67 enrolled
Drug / intervention
IM olanzapine +1 moredrug
Likely dose
IM olanzapine 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00797277
NCT00797277Phase 3Completed
CompareCT.gov

An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia

National Taiwan University Hospital·interventional·Posted Nov 25, 2008·Updated Sep 15, 2014

In Brief

A Phase 3 clinical trial evaluating IM olanzapine and IM haloperidol plus lorazepam for Schizophrenia and 2 related conditions. Completed, enrolled 67 participants across 1 site.

Detailed Summary

The aim of this study was to compare the efficacy and safety of intramuscular 10 mg olanzapine versus intramuscular 5 mg haloperidol plus lorazepam 2 mg in the treatment of acute agitated schizophrenic patients of Taiwanese populations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder, Agitation
CountriesTaiwan
CollaboratorsYu-Li Hospital

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 25, 2008
Enrollment StartJul 1, 2006
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.6 years ago

Interventions

IM olanzapinedrug

10mg olanzapine IM

IM haloperidol plus lorazepamdrug

IM 5 mg haloperidol plus IM 2 mg lorazepam